



10th August, 2023

Ref:- GH/2023-24/EXCH/34

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (*'Listing Regulations'*)

Dear Sir(s),


We would like to inform you that the Board of Directors of Global Health Limited (**'GHL/Company'**) at its meeting held today i.e. *Thursday, August 10, 2023*, has *inter alia*, approved:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the First Quarter ended June 30, 2023 (**'Results'**); and
2. To Convene the 19th Annual General Meeting of the Company to be held on *Wednesday, September 20, 2023*, at *12 Noon* through Video Conferencing/Other Audio Video Means (**'VC/OAVM'**) Facility.

The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiook & Co LLP, Chartered Accountants thereon, are enclosed herewith pursuant to Regulation 33 of the Listing Regulations.

The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.

In addition, the Board has also approved a Binding Term Sheet with DLF Limited (**'DLF'**) wherein a Special Purpose Vehicle (**'SPV'**) will be incorporated by GHL, to set up approx. 400 bed multi-speciality hospital in Delhi. The Proposed SPV shall be a Public Limited Company and have 50:50 Equity Shareholding of the GHL and DLF. A copy of the Press Release on the same, will also be intimated to the Stock Exchanges.





Global Health L i m i t e d

The details as required under Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in Annexure A.

The meeting of the Board of Directors commenced at 1.00 P.M. and concluded at 3:20 P.M.

Thanking You,

For Global Health Limited



Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a



Annexure A

Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

| S. No. | Particulars | Details |
|--------|---|---|
| 1. | Name(s) of parties with whom the agreement is entered | GHL and DLF |
| 2. | Purpose of entering into the agreement | Under the binding term sheet, GHL will incorporate a Special Purpose Vehicle ("SPV") to construct, equip and operate super specialty hospitals, clinics and health care centres with other related ancillary medical facilities and services ("Hospitals/Project"). SPV shall be a Public Limited Company and have 50:50 Equity Shareholding of the GHL and DLF. |
| 3. | Shareholding, if any, in the entity with whom the agreement is executed | NIL |
| 4. | Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc. | Significant terms of the term sheet include the following: (i) SPV will be incorporated as a wholly-owned public limited Company. (ii) Shareholding: SPV will have 50:50 equity shareholding of GHL and DLF. (iii) Initial Subscribed Capital: Rs. 10,00,000/- or such other nominal amount as may be mutually agreed. (iv) Board Composition: (a) Minimum 04 directors - 02 GHL Nominee Directors (at least 1 shall be an Executive Director) and 02 DLF Nominee Directors, (both will be Non-Executive Directors). |





Global Health L i m i t e d

(b) In case of requirement of Independent Director(s), then 02 Independent Directors shall be appointed in the Board.

(c) Until Dr. Trehan/ his affiliates (i.e., family, entities controlled by them and family trust, if any) continue to hold or control 16% of the shareholding of GHIL, GHIL Nominee Director will be the chairperson of the SPV and will have the casting vote which are not Reserved Matters.

(d) In the event Dr Trehan's/ his affiliates' shareholding in GHIL drops below 16% but DLF continues to hold 50% shareholding in the SPV, then, a DLF Nominee Director will be the chairperson of the SPV. However, such chairperson will not have the right to a casting vote.

(e) In the event the shareholding of Dr. Trehan/ his affiliates in GHIL falls below 16% and DLF's shareholding in the SPV falls below 50%, then, the Board of the SPV will appoint the chairperson of the SPV. Such chairperson will not have the right to a casting vote.


(v) Reserved Matters: Reserved Matters will require the approval of both Parties before it is introduced in Board meeting. It is clarified that the chairpersons of the Board will not have the casting vote with respect to any of the Reserved Matter.

(vi) Restriction on Transfer of Shares: Shares cannot be transferred during the construction period of the Hospitals and for a period of 05 (five) years from the date of commencement of Hospitals operations ("Lock-in Period").



Global Health L i m i t e d

| | | |
|----|--|---|
| | | <p>Post Lock-in Period, the shares can be transferred to any third party except a competitor, subject to non-transferring party's:</p> <p>(a) right of first refusal (ROFR); (b) tag along rights; (c) non-compete obligations; and (d) execution of deed of adherence.</p> <p>(vii) Consequence of Uncured Event of Default (EOD): Upon EOD, the non-defaulting party shall have the right to: (i) call upon the defaulting party to sell its shares at 90% of the fair market value; or (ii) put the shares held by non-defaulting party in the SPV to the defaulting party at 110% of the fair market value of the shares.</p> |
| 5. | Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship | No |
| 6. | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length" | No |
| 7. | In case of issuance of shares to the parties, details of issue price, class of shares issued | Not Applicable |
| 8. | Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc. | Nil, except as disclosed in Item No. 4 above. |
| 9. | in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof. | Not Applicable |



Walker ChandioK & Co LLP

11th Floor, Tower II,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited (formerly Global Health Private Limited)

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Global Health Limited (formerly Global Health Private Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with
limited liability with identification number
AAC-2085 and its registered office at L-41
Connaught Circus, New Delhi, 110001, India



Walker Chandiook & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Rajni Mundra

Rajni Mundra

Partner

Membership No. 058644



UDIN: 23058644BGXZPU3304

Place: Mumbai

Date: 10 August 2023

Walker ChandioK & Co LLP

Annexure I to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

| S. No. | Name | Relationship with the Holding Company |
|--------|--|---------------------------------------|
| 1 | Medanta Holdings Private Limited | Wholly owned subsidiary |
| 2 | Global Health Patliputra Private Limited | Wholly owned subsidiary |
| 3 | GHL Pharma & Diagnostic Private Limited | Wholly owned subsidiary |



(This space has been intentionally left blank)

Global Health Limited (formerly known as Global Health Private Limited)
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN: L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: <https://www.medanta.org>

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2023

(₹ in lakhs)

| S No. | Particulars | Quarter ended | | | Year ended |
|-------|--|------------------|-----------------------------|------------------|--------------------|
| | | 30 June 2023 | 31 March 2023 | 30 June 2022 | 31 March 2023 |
| | | (Unaudited) | (Audited) (Refer note 9) | (Audited) | (Audited) |
| | Income | | | | |
| I | Revenue from operations | 77,303.96 | 70,342.18 | 61,744.90 | 2,69,424.83 |
| II | Other income | 2,145.91 | 2,840.64 | 909.46 | 6,491.48 |
| | Total income | 79,449.87 | 73,182.82 | 62,654.36 | 2,75,916.31 |
| | Expenses | | | | |
| III | Cost of materials consumed | 16,451.69 | 15,060.66 | 13,506.94 | 57,112.47 |
| | Purchases of stock-in-trade | 1,829.84 | 1,618.76 | 1,349.99 | 5,573.78 |
| | Changes in inventories of stock-in-trade | (144.40) | (202.08) | (139.17) | (157.70) |
| | Employee benefits expense | 17,792.46 | 15,891.62 | 15,554.23 | 63,434.54 |
| | Finance costs | 1,791.60 | 2,048.03 | 1,853.21 | 7,791.93 |
| | Depreciation and amortisation expense | 4,038.30 | 3,795.00 | 3,607.87 | 14,991.48 |
| | Impairment losses on financial assets | 644.07 | 285.15 | 51.74 | 761.87 |
| | Retainers and consultants fee | 10,002.40 | 9,096.34 | 7,375.20 | 33,301.13 |
| | Other expenses | 12,939.67 | 12,281.43 | 10,791.08 | 48,177.84 |
| | Total expenses | 65,345.63 | 59,874.91 | 53,951.09 | 2,30,987.28 |
| IV | Profit before tax | 14,104.24 | 13,307.91 | 8,703.27 | 44,929.03 |
| V | Tax expenses | | | | |
| | Current tax | 4,191.83 | 2,228.96 | 2,405.40 | 9,736.19 |
| | Deferred tax (credit)/charge | (288.61) | 971.68 | 426.58 | 2,584.91 |
| VI | Profit after tax | 10,201.02 | 10,107.27 | 5,871.29 | 32,607.93 |
| | Other comprehensive income | | | | |
| A | (i) Items that will not be reclassified to statement of profit or loss | (314.29) | 108.79 | 68.95 | 186.37 |
| | (ii) Income-tax relating to items that will not be reclassified to statement of profit or loss | 73.45 | (26.21) | (17.15) | (44.21) |
| B | (i) Items that will be reclassified to profit or loss | - | - | - | - |
| | (ii) Income-tax relating to items that will be reclassified to profit or loss | - | - | - | - |
| VII | Total other comprehensive income | (240.84) | 82.58 | 51.80 | 142.16 |
| VIII | Total comprehensive income | 9,960.18 | 10,189.85 | 5,923.09 | 32,750.09 |
| | Profit after tax attributable to: | | | | |
| | (i) Owners of the Holding Company | 10,201.02 | 10,107.27 | 5,871.29 | 32,607.93 |
| | (ii) Non-controlling interests | - | - | - | - |
| | Other comprehensive income attributable to: | | | | |
| | (i) Owners of the Holding Company | (240.84) | 82.58 | 51.80 | 142.16 |
| | (ii) Non-controlling interests | - | - | - | - |
| | Total comprehensive income attributable to: | | | | |
| | (i) Owners of the Holding Company | 9,960.18 | 10,189.85 | 5,923.09 | 32,750.09 |
| | (ii) Non-controlling interests | - | - | - | - |
| IX | Paid-up equity share capital (face value of ₹ 2 each) | 5,365.35 | 5,363.90 | 5,064.48 | 5,363.90 |
| X | Reserves (other equity) | | | | 2,37,456.92 |
| XI | Earnings per share (face value of ₹ 2 each) (not annualised for the quarters) | | | | |
| | Basic (₹ per share) | 3.80 | 3.77 | 2.32 | 12.58 |
| | Diluted (₹ per share) | 3.80 | 3.76 | 2.31 | 12.57 |

See accompanying notes to the consolidated unaudited financial results



**SIGNED FOR
IDENTIFICATION
PURPOSES ONLY**



Global Health Limited (formerly known as Global Health Private Limited)
Notes to the consolidated unaudited financial results:

- 1 The above consolidated unaudited financial results of Global Health Limited (formerly known as Global Health Private Limited) (the Holding Company) and its wholly owned subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the quarter ended 30 June 2023 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10 August 2023 and a limited review of the same has been carried out by its statutory auditors.
- 2 These consolidated unaudited financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Group's performance from a service perspective and has identified the 'Healthcare Services' as single business segment. The Group is operating in India which constitutes a single geographical segment. Accordingly, no other disclosures are required to be furnished per Ind AS 108 'Operating Segments'.
- 4 During the year ended 31 March 2023, the Holding Company had completed its Initial Public Offer (IPO) of 65,641,952 equity shares of face value of ₹ 2 each for cash at a price of ₹ 336 per equity share (including a share premium of ₹ 334 per equity share) aggregating to ₹ 220,556.96 lakhs. This comprises of fresh issue of 14,880,952 equity shares aggregating up to ₹ 50,000 lakhs ('fresh issue') and an offer for sale of 50,761,000 equity shares aggregating to ₹ 170,556.96 lakhs. The equity shares of the Holding Company got listed with BSE Limited and National Stock Exchange of India Limited on 16 November 2022.

The utilisation of the IPO proceeds is summarised below:

| (₹ in lakhs) | | | |
|--|--|----------------------------|--|
| Object of the issue as per prospectus | Utilisation planned as per prospectus* | Utilised upto 30 June 2023 | Amount pending for utilisation as 30 June 2023 # |
| Investment in the form of debt, equity or repayment/prepayment of the borrowings in full or part in the wholly owned subsidiaries, Global Health Patliputra Private Limited and Medanta Holdings Private Limited | 37,500.00 | 37,500.00 | - |
| General corporate purposes | 10,170.10 | 1,042.70 | 9,127.40 |

* Net of share issue expense of ₹ 2,329.90 lakhs

#The above mentioned unutilised proceeds have been temporarily invested in deposits with banks.

- 5 During the quarter, the Holding Company has allotted 72,210 equity shares under the Holding Company's Employee Stock Options Schemes on exercise of vested options by eligible employees.
- 6 Subsequent to quarter-end, the Holding Company and DLF Limited have executed a binding term sheet for forming a special purpose vehicle to set up a 400 bed multi-speciality hospital in Delhi.
- 7 During the year ended 31 March 2023, the Board of Directors of the Holding Company had approved a binding term sheet for a new hospital at Indore on Operation and Management basis. The due diligence is still in process, but, the said term sheet is now non-binding in nature.
- 8 During the quarter, long-term credit rating of the Holding Company got upgraded from 'CRISIL A+/Positive' to 'CRISIL AA-/Stable' and short-term credit rating was reaffirmed at 'CRISIL A1+'.
- 9 The figures for the quarter ended 31 March 2023, are the balancing figures between the audited figures for the year ended 31 March 2023 and the unaudited published year to date figures for 31 December 2022.
- 10 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited
(formerly known as Global Health Private Limited)


Dr. Naresh Trehan
Chairman and Managing Director

Place: Gurugram
Date : 10 August 2023



**SIGNED FOR
IDENTIFICATION
PURPOSES ONLY**



Walker ChandioK & Co LLP

11th Floor, Tower II,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited (formerly Global Health Private Limited)

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited (formerly Global Health Private Limited) ('the Company') for the quarter ended 30 June 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

Walker ChandioK & Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Rajni Mundra

Rajni Mundra

Partner

Membership No. 058644



UDIN: 23058644BGXZPV8310

Place: Mumbai

Date: 10 August 2023

Global Health Limited (formerly known as Global Health Private Limited)
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta - The Medicity, Sector - 38, Gurgaon, Haryana - 122001, India
CIN: L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org
Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2023

(₹ In lakhs)

| S No. | Particulars | Quarter ended | | | Year ended |
|-------|--|------------------|------------------------------|------------------|--------------------|
| | | 30 June 2023 | 31 March 2023 | 30 June 2022 | 31 March 2023 |
| | | (Unaudited) | (Audited) (Refer note 10) | (Audited) | (Audited) |
| | Income | | | | |
| I | Revenue from operations | 54,458.80 | 50,290.99 | 47,267.01 | 1,95,944.62 |
| II | Other income | 3,320.26 | 2,810.21 | 787.86 | 6,168.29 |
| | Total income | 57,779.06 | 53,101.20 | 48,054.87 | 2,02,112.91 |
| | Expenses | | | | |
| III | Cost of materials consumed | 12,033.46 | 11,247.48 | 10,418.05 | 43,010.47 |
| | Purchases of stock-in-trade | 1,114.99 | 1,059.52 | 943.63 | 3,590.34 |
| | Changes in inventories of stock-in-trade | (102.01) | (190.16) | (85.37) | (40.65) |
| | Employee benefits expense | 14,572.26 | 13,127.76 | 13,189.79 | 53,163.41 |
| | Finance costs | 638.14 | 637.90 | 664.91 | 2,616.14 |
| | Depreciation and amortisation expense | 2,042.80 | 2,035.42 | 2,184.45 | 8,608.86 |
| | Impairment losses on financial assets | 634.12 | 278.47 | 51.73 | 746.24 |
| | Retainers and consultants fee | 5,472.91 | 4,993.53 | 4,200.65 | 18,417.81 |
| | Other expenses | 9,798.55 | 9,491.90 | 8,266.37 | 36,829.79 |
| | Total expenses | 46,205.22 | 42,681.82 | 40,034.21 | 1,66,942.41 |
| IV | Profit before tax | 11,573.84 | 10,419.38 | 8,020.66 | 35,170.50 |
| V | Tax expense | | | | |
| | Current tax | 3,455.00 | 2,228.96 | 2,405.40 | 9,736.19 |
| | Defer tax (credit)/charge | (502.30) | 94.88 | (204.28) | (890.21) |
| VI | Profit after tax | 8,621.14 | 8,095.54 | 5,819.54 | 26,324.52 |
| | Other comprehensive income | | | | |
| | A (i) Items that will not be reclassified to statement of profit or loss | (285.77) | 97.16 | 63.78 | 154.86 |
| | (ii) Income-tax relating to items that will not be reclassified to statement of profit or loss | 71.92 | (24.46) | (16.05) | (38.98) |
| | B (i) Items that will be reclassified to profit or loss | - | - | - | - |
| | (ii) Income-tax relating to items that will be reclassified to profit or loss | - | - | - | - |
| VII | Total other comprehensive income | (213.85) | 72.70 | 47.73 | 115.88 |
| VIII | Total comprehensive income | 8,407.29 | 8,168.24 | 5,867.27 | 26,440.40 |
| IX | Paid-up equity share capital (face value of ₹ 2 each) | 5,365.35 | 5,363.90 | 5,064.48 | 5,363.90 |
| X | Reserves (other equity) | | | | 2,43,521.77 |
| XI | Earnings per share (face value of ₹ 2 each) (not annualised for the quarters) | | | | |
| | Basic (₹ per share) | 3.21 | 3.02 | 2.30 | 10.16 |
| | Diluted (₹ per share) | 3.21 | 3.02 | 2.29 | 10.15 |

See accompanying notes to the standalone unaudited financial results



**SIGNED FOR
IDENTIFICATION
PURPOSES ONLY**



Global Health Limited (formerly known as Global Health Private Limited)

Notes to the standalone unaudited financial results :

- The standalone unaudited financial results for the quarter ended 30 June 2023 of Global Health Limited (formerly known as Global Health Private Limited) (the Company) has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10 August 2023 and a limited review of the same has been carried out by its statutory auditors.
- These standalone unaudited financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 (the Act), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified Healthcare Services as single business segment. The Company is operating in India which constitutes a single geographical segment. Accordingly, no other disclosures are required to be furnished per Ind AS 108 'Operating Segment'.
- During the quarter ended 30 June 2023, the Company has infused unsecured loans amounting to ₹ 12,500 lakhs and ₹ 25,000 lakhs to its wholly owned subsidiaries, namely, Global Health Patliputra Private Limited and Medanta Holdings Private Limited, respectively.
- During the year ended 31 March 2023, the Company had completed its Initial Public Offer (IPO) of 65,641,952 equity shares of face value of ₹ 2 each for cash at a price of ₹ 336 per equity share (including a share premium of ₹ 334 per equity share) aggregating to ₹ 220,556.96 lakhs. This comprises of fresh issue of 14,880,952 equity shares aggregating up to ₹ 50,000 lakhs (fresh issue) and an offer for sale of 50,761,000 equity shares aggregating to ₹ 170,556.96 lakhs. The equity shares of the Company got listed at BSE Limited and National Stock Exchange of India Limited on 16 November 2022.

The utilisation of the IPO is summarised below:


| | (₹ in lakhs) | | |
|--|--|----------------------------|---|
| Object of the issue as per prospectus | Utilisation planned as per prospectus* | Utilised upto 30 June 2023 | Amount pending for utilisation as 30 June 2023 \$ |
| Investment in the form of debt, equity or repayment/prepayment of the borrowings in full or part in the wholly owned subsidiaries, Global Health Patliputra Private Limited and Medanta Holdings Private Limited | 37,500.00 | 37,500.00 | - |
| General corporate purposes | 10,170.10 | 1,042.70 | 9,127.40 |

* Net of share issue expense of ₹ 2,329.90 lakhs

\$ The above mentioned unutilised IPO proceeds have been temporarily invested in deposits with banks.

- During the quarter, the Company has allotted 72,210 equity shares under the Company's Employee Stock Options Schemes on exercise of vested options by eligible employees.
- Subsequent to quarter-end, the Company and DLF Limited have executed a binding term sheet for forming a special purpose vehicle to set up a 400 bed multi-speciality hospital in Delhi.
- During the year ended 31 March 2023, the Board of Directors of the Company had approved a binding term sheet for a new hospital at Indore on Operation and Management basis. The due diligence is still in process, but, the said term sheet is now non-binding in nature.
- During the quarter, long-term credit rating of the Company got upgraded from 'CRISIL A+/Positive' to 'CRISIL AA-/Stable' and short-term credit rating was reaffirmed at 'CRISIL A1+'.
- The figures for the quarter ended 31 March 2023, are the balancing figures between the audited figures for the year ended 31 March 2023 and the unaudited published year to date figures for 31 December 2022.
- Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited
(formerly known as Global Health Private Limited)


Dr. Naresh Trehan
Chairman and Managing Director

Place: Gurugram
Date : 10 August 2023



**SIGNED FOR
IDENTIFICATION
PURPOSES ONLY**

